Dr. Jackman on Overcoming Resistance to EGFR Inhibitors in Lung Cancer

David M. Jackman, MD
Published: Monday, Mar 27, 2017



David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

When patients develop resistance to their first EGFR inhibitors, they often have T790M mutations. This lead to the development of osimertinib (Tagrisso), adds Jackman.

Resistance in NSCLC is very specific, says Jackman, and as resistance becomes better understood, more targeted therapies can be developed.
 


David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

When patients develop resistance to their first EGFR inhibitors, they often have T790M mutations. This lead to the development of osimertinib (Tagrisso), adds Jackman.

Resistance in NSCLC is very specific, says Jackman, and as resistance becomes better understood, more targeted therapies can be developed.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x